Zhengye Biotechnology Holding (ZYBT) Non-Current Debt (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Non-Current Debt for 3 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non-Current Debt rose 86.73% year-over-year to $1.2 million in Q4 2025; TTM through Dec 2025 was $1.2 million, a 86.73% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 92.4% from the prior year.
• Non-Current Debt was $1.2 million for Q4 2025 at Zhengye Biotechnology Holding, up from $656000.0 in the prior quarter.
• Over five years, Non-Current Debt peaked at $1.4 million in Q4 2023 and troughed at $656000.0 in Q2 2025.
• A 3-year average of $989876.3 and a median of $958010.0 in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt plunged 51.84% in 2024 and surged 86.73% in 2025, its largest moves.
• Over 3 years, Non-Current Debt stood at $1.4 million in 2023, then sank by 51.84% to $668235.5 in 2024, then surged by 86.73% to $1.2 million in 2025.
• The last three Non-Current Debt figures came in at $1.2 million (Q4 2025), $656000.0 (Q2 2025), and $668235.5 (Q4 2024), per Business Quant data.